Novo Nordisk A/S filed its 2023 Remuneration Report on January 31, 2024, detailing a 36% sales increase to DKK 232.3 billion and a 51% rise in net profit. The filing also discusses executive compensation with the CEO earning DKK 68.2 million, highlighting significant company growth driven by demand for diabetes and obesity medications.